Evaxion Biotech A/S - Expects Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Oper Expenses and Capex Requirements Into Q1 2025
Evaxion Biotech A/S——預計現有的現金和現金等價物將足以爲2025年第一季度的運營支出和資本支出需求提供資金
Evaxion Biotech A/S - Expects Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Oper Expenses and Capex Requirements Into Q1 2025
Evaxion Biotech A/S——預計現有的現金和現金等價物將足以爲2025年第一季度的運營支出和資本支出需求提供資金
譯文內容由第三人軟體翻譯。